News

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
BioSpace2d
5 Alzheimer’s Readouts To Watch
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...
Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
The FDA must crack down on dangerous knockoff weight-loss drugs
Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...
What happens when you stop taking Ozempic for weight loss?
What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...
Lexaria Bioscience Corp.: Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
The Print on MSN4d
India sees 20k bariatric surgeries a year. But blockbusters Mounjaro, Wegovy are shaking up obesity arena
India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
BioSpace2d
As Alzheimer’s Space Heats Up, Biopharma Leans In to Holistic Treatment
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update
Cash position of €7.1 million as of June 30, 2025 US$10 million milestone payment from partner Tonghua Dongbao and 2024 Research Tax Credit of €2.8 million received in July 2025 Current ...